Page last updated: 2024-11-02

phentermine and Metabolic Syndrome

phentermine has been researched along with Metabolic Syndrome in 3 studies

Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.

Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.

Research Excerpts

ExcerptRelevanceReference
"OBJECTIVE To evaluate over 108 weeks the effect of phentermine and topiramate extended release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or cardiometabolic disease in subjects with prediabetes and/or metabolic syndrome (MetS) at baseline."9.19Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. ( Bohannon, NJ; Day, WW; Garvey, WT; Henry, R; Ryan, DH; Schwiers, M; Toplak, H; Troupin, B, 2014)
"OBJECTIVE To evaluate over 108 weeks the effect of phentermine and topiramate extended release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or cardiometabolic disease in subjects with prediabetes and/or metabolic syndrome (MetS) at baseline."5.19Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. ( Bohannon, NJ; Day, WW; Garvey, WT; Henry, R; Ryan, DH; Schwiers, M; Toplak, H; Troupin, B, 2014)
" Food and Drug Administration has approved three weight loss agents: sibutramine, orlistat, and phentermine."4.83Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. ( Pi-Sunyer, FX, 2006)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Garvey, WT1
Ryan, DH1
Henry, R1
Bohannon, NJ1
Toplak, H1
Schwiers, M1
Troupin, B1
Day, WW1
Ueno, H1
Nakazato, M1
Pi-Sunyer, FX1

Reviews

2 reviews available for phentermine and Metabolic Syndrome

ArticleYear
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3

    Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical

2014
Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors.
    Obesity (Silver Spring, Md.), 2006, Volume: 14 Suppl 3

    Topics: Caloric Restriction; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus; Diet; Diet, Fat-Restr

2006

Trials

1 trial available for phentermine and Metabolic Syndrome

ArticleYear
Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release.
    Diabetes care, 2014, Volume: 37, Issue:4

    Topics: Anti-Obesity Agents; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Female; Fructose; Human

2014